Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nithya Ramnath

Showing results (21-30 of 142) with videos related to

Pageof 15
Sort By:
The Indian Journal of Medical Research|February 6, 2025
Lung cancer screening in India: Preparing for the future using smart tools & biomarkers to identify highest risk individualsNithya Ramnath, Prasanth Ganesan, Prasanth Penumadu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2016
Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case StudyZhuo Zhang, Hiroe Shiratsuchi, Nallasivam Palanisamy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Malignant pleural mesothelioma after household exposure to asbestosAnush V Patel, Paul N Bogner, Donald Klippenstein, et al.
Cancer Medicine|July 16, 2016
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancerAngel Qin, David G Coffey, Edus H Warren, et al.
International Journal of Cancer|December 4, 2004
Nuclear or cytoplasmic expression of survivin: what is the significance?Fengzhi Li, Jie Yang, Nithya Ramnath, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2014
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancerMeaghan O'Malley, Amanda N King, Marisa Conte, et al.
Oncology|January 6, 2009
Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experienceSikander Ailawadhi, Lyudmyla Derby, Raj Natarajan, et al.
Journal of Thoracic Disease|March 15, 2021
Characterization of pneumonia and other factors leading to poorer survival across all age groups in patients with non-small cell lung cancer (NSCLC)Frank D Weinberg, Lili Zhao, Niranjana Chellappa, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|June 16, 2007
What did you think of the hematology/oncology rotation? A survey of internal medicine residentsHongbin Chen, Amir Mortazavi, Ellis Levine, et al.
American Journal of Clinical Oncology|February 6, 2004
Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experienceFrancisco J Hernandez-Ilizaliturri, Dongfeng Tan, David Cipolla, et al.
Pageof 15

Showing results (21-30 of 142) with videos related to

Sort By:
Pageof 15
The Indian Journal of Medical Research|February 6, 2025
Lung cancer screening in India: Preparing for the future using smart tools & biomarkers to identify highest risk individualsNithya Ramnath, Prasanth Ganesan, Prasanth Penumadu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2016
Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case StudyZhuo Zhang, Hiroe Shiratsuchi, Nallasivam Palanisamy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Malignant pleural mesothelioma after household exposure to asbestosAnush V Patel, Paul N Bogner, Donald Klippenstein, et al.
Cancer Medicine|July 16, 2016
Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancerAngel Qin, David G Coffey, Edus H Warren, et al.
International Journal of Cancer|December 4, 2004
Nuclear or cytoplasmic expression of survivin: what is the significance?Fengzhi Li, Jie Yang, Nithya Ramnath, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 14, 2014
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancerMeaghan O'Malley, Amanda N King, Marisa Conte, et al.
Oncology|January 6, 2009
Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experienceSikander Ailawadhi, Lyudmyla Derby, Raj Natarajan, et al.
Journal of Thoracic Disease|March 15, 2021
Characterization of pneumonia and other factors leading to poorer survival across all age groups in patients with non-small cell lung cancer (NSCLC)Frank D Weinberg, Lili Zhao, Niranjana Chellappa, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|June 16, 2007
What did you think of the hematology/oncology rotation? A survey of internal medicine residentsHongbin Chen, Amir Mortazavi, Ellis Levine, et al.
American Journal of Clinical Oncology|February 6, 2004
Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experienceFrancisco J Hernandez-Ilizaliturri, Dongfeng Tan, David Cipolla, et al.
Pageof 15